Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GCK | P35557 | 9/20 | 0.40 |
| ▸ | RARA | P10276 | 1/20 | 0.40 |
| ▸ | RARB | P10826 | 1/20 | 0.40 |
| ▸ | RARG | P13631 | 1/20 | 0.40 |
| ▸ | WDR5 | P61964 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL151012 | 0.86 | KMT2A (0.64) | KMT2ARXRARXRBALDH1A1GCK | |
| SCHEMBL31550001 | 0.86 | AURKA (0.56) | KMT2AAURKATPX2ALDH1A1WDR5 | |
| SCHEMBL2568060 | 0.86 | CA12 (0.49) | KMT2AFFAR4ALDH1A1FAAHEPHX2 | |
| SCHEMBL23411501 | 0.85 | AURKA (0.47) | AURKATPX2ALDH1A1WDR5MRGPRX4 | |
| SCHEMBL29728803 | 0.85 | AURKA (0.47) | AURKATPX2ALDH1A1WDR5MRGPRX4 | |
| SCHEMBL1793221 | 0.83 | KMT2A (0.49) | KMT2ARXRARXRBALDH1A1GCK | |
| SCHEMBL475754 | 0.82 | AURKA (0.56) | KMT2AAURKATPX2ALDH1A1WDR5 | |
| SCHEMBL17060010 | 0.82 | KMT2A (0.64) | KMT2ARXRARXRBALDH1A1GCK | |
| SCHEMBL18890162 | 0.81 | RXRA (0.50) | FFAR4AURKATPX2RXRAWDR5 | |
| SCHEMBL29394747 | 0.81 | RXRA (0.50) | FFAR4AURKATPX2RXRAWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222668-B1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARM INC (US) | 2011-11-02 | — | — | EP | disclosed |
| CN-101945862-A | Tetrahydrocyclopenta [ b ] indol-3-yl carboxylic acid derivatives for the treatment of autoimmune and inflammatory disorders | ARENA PHARM INC | 2011-01-12 | — | — | CN | disclosed |
| US-20100273806-A1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | US | disclosed |
| EP-2222668-A1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | Arena Pharmaceuticals, Inc. (US) | 2010-09-01 | — | — | EP | disclosed |
| WO-2009078983-A1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273806-A1 | TETRAHYDROCYCLOPENTA[B]INDOL-3-YL CARBOXYLIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | KMT2A 3974/4885FFAR4 35/4885AURKA 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.